#United States #Austin #Pain Management #Neuromodulation #BioWave

BioWave® Introduces New Clinical Data for Pain Relief

BioWave® Corp., a frontrunner in non-invasive neuromodulation technology, has reported positive interim results from two pivotal studies presented at the 2025 American Society of Regional Anesthesia and Pain Medicine Annual Meeting held in Austin, Texas. The findings underscore the clinical efficacy of BioWave's patented high-frequency neuromodulation technology in addressing various pain conditions, from severe battlefield injuries in Ukraine to home-based pain management solutions for patients with chronic ailments.

Aiding Ukrainian Soldiers

The first of the two studies, carried out in collaboration with Imperial College Healthcare in London and the Regional Clinical Hospital of Ivano-Frankivsk, Ukraine, focused on around 50 patients who suffered from serious battlefield injuries such as limb amputations and nerve damage. The results were compelling:

• - Average pain scores dropped significantly from 6.68 to 3.24 immediately after treatment, determined by the visual analog scale (VAS).
• - Patients experienced a mean lasting pain relief of 17.2 hours following a single 30-minute session with the BioWave device.
• - Enhanced comfort and improved mobility were noted, leading to better prosthetic use and decreased phantom limb pain in amputees.
• - The treatments exhibited high tolerability, with no adverse events reported, and repeat sessions maintained consistent benefits over time.

Battlefield injuries necessitate immediate care; however, long-term pain management remains a critical issue. Many of these patients endure chronic pain conditions post-amputation due to inadequate medical resources, a deficit of specialized care, and the ongoing challenges posed by war environments. These issues can hinder rehabilitation and affect overall recovery. BioWave’s non-invasive neuromodulation technology provides an alternative, offering an effective and drug-free treatment option that can be administered in various settings, including hospitals, field locations, or at home. The ability to rapidly reduce pain, minimize long-term medication requirements, and enhance physical function can significantly improve patients' experiences, allowing for an easier transition back into rehabilitation and day-to-day life.

Brad Siff, Founder and President of BioWave, expressed gratitude for the opportunity to contribute to the study and recognized the hard work of clinicians such as Dr. Nadiya Segin and Dr. Arun Bhaskar. "These findings highlight the potential for our technology to make a difference in resource-limited environments, playing a critical role in accelerating rehabilitation, decreasing reliance on medications, and enhancing quality of life for injured service members," he commented.

Supporting Home-Based Patients

The second study presented at the ASRA Pain Medicine meeting by the team of Arun Kumar Bhaskar, Helen Walsh, and Dominic Hegarty analyzed over 10,400 patient outcomes, correlating feedback from public channels. This research explored the use of BioWave devices in home environments for managing a variety of chronic pain issues, including back pain (42%), shoulder pain (14%), and neck or headache pain (13%).
Key findings from this analysis demonstrated:

• - Patients reported a significant improvement, with pain scores decreasing from 7.8 to 3.9 (VAS).
• - An impressive 93% of participants noted an enhancement in their quality of life.
• - Medication intake decreased by 43% in users, leading to either reduced or eliminated reliance on pain medications.
• - Over half of the users reported improved mood and sleep, with 65% and 56% respectively, highlighting overall well-being.
• - A remarkable 97% of users expressed their willingness to continue leveraging BioWave therapy for ongoing pain management.

This second study solidifies BioWave’s position as an effective and non-invasive solution for chronic pain management, achieving significant amelioration of discomfort while also decreasing the requirement for pharmaceutical interventions and enhancing patients' physical mobility. By providing precise, targeted pain relief without the need for surgical procedures or implants, BioWave's neuromodulation technology offers a safe and sustainable alternative, catering to both clinical and home use.

Siff emphasized, "These results represent a paradigm shift in pain management. Unlike traditional neuromodulation methods that often rely on invasive devices, our non-invasive technology introduces a more accessible and affordable solution for those suffering from chronic pain." He concluded, “The studies shared at ASRA reaffirm the extraordinary impact our technology can have, whether aiding soldiers in dire need of recovery or patients managing chronic pain in their homes."

About BioWave

BioWave stands as an FDA-cleared, patented technology designed to block pain at its source through its innovative Smarter Pain Blocking Technology®. The company focuses on enhancing patient outcomes by offering portable, effective pain relief without drug side effects. Initially developed for athletes seeking expedited recovery, BioWave has since garnered the trust of healthcare providers across the U.S, including Federal Healthcare VA Clinics, helping veterans manage pain and improve their quality of life. To learn more, visit www.biowave.com.